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Drug resistance to 5-fluorouracil (5-FU) is still a major limitation to its clinical use. In addition, the clinical value of p53 as a predictive marker
for 5-FU-based chemotherapy remains a matter of debate. Here, we used HCT116 human colorectal cancer cells expressing wild-type p53 and
investigated whether inhibition of Fas expression by interference RNA modulates 5-FU-induced apoptosis. Cells were treated with 5-FU (1, 4 or
8 μM) for 8–48 h. Cell viability was evaluated by trypan blue dye exclusion. Apoptosis was assessed by changes in nuclear morphology and
caspase activity. The interference RNA technology was used to silence Fas expression. Caspase activation, p53, Fas, cytochrome c, and Bcl-2
family protein expression was evaluated by immunoblotting. 5-FU was cytotoxic in HCT116 cells (p<0.001). Nuclear fragmentation and caspase-
3, -8 and -9 activities were also markedly increased in HCT116 cells after 5-FU (p<0.001). In addition, wild-type p53 and Fas expression were 25-
and 4-fold increased (p<0.05). Notably, when interference RNA was used to inhibit Fas, 5-FU-mediated nuclear fragmentation and caspase
activity were markedly reduced in HCT116 cells. Finally, western blot analysis of mitochondrial extracts from HCT116 cells exposed to 5-FU
showed a 6-fold increase in Bax, together with a 3-fold decrease in cytochrome c (p<0.001). In conclusion, 5-FU exerts its cytotoxic effects, in
part, through a p53/Fas-dependent apoptotic pathway that involves Bax translocation and mitochondrial permeabilization.
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The main goal in cancer therapy is the abrogation of tumor
cell growth and proliferation, and ultimately the complete
elimination of tumor cells. This can be achieved by either
activation of cell death programs, correction of non-functional
metabolic pathways, or reduction of drug efflux from cancer
cells. Further, it is commonly accepted that tumor cells treated
with anticancer agents undergo apoptosis, and that cells resistantAbbreviations: 5-FU, 5-fluorouracil; siRNA, short interference RNA
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doi:10.1016/j.bbadis.2006.09.005to apoptosis often do not respond to anticancer therapy [1].
However, other determinants of drug resistance exist, including
loss of cell surface receptors or transporters, altered metabolism,
or mutation of specific target [2].
5-Fluorouracil (5-FU) has been a key drug in the treatment of
colorectal cancer for more than 40 years. However, tumor cell
resistance remains a significant limitation to the clinical use of 5-
FU [3]. The mechanism of 5-FU cytotoxicity has been attributed
to misincorporation of fluoronucleotides into RNA and DNA
and to inhibition of the nucleotide synthetic enzyme thymidylate
synthase [3]. Further, 5-FU induces apoptosis in normal
intestinal cells [4] and in a number of colon cancer cell lines
[5,6]. Other reports have demonstrated that 5-FU-induced
apoptosis is dependent on the tumor suppressor p53 protein
[5,7,8], although apoptosis can also occur in mutant p53 cell
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cated in chemoresistance of colon cancer cells and, therefore,
alterations in the mediators of 5-FU-induced apoptosis may
account for 5-FU resistance [11]. Thus, understanding its mole-
cular mechanisms of action is pivotal to overcoming tumor cell
resistance and improving overall chemotherapy efficacy.
The tumor suppressor p53 gene plays a major role in
preventing tumorigenesis, by responding to both cellular stress
and DNA damage [12]. In fact, p53 is stabilized by inhibition of
its degradation in response to a wide range of stresses, including
DNA damage, aberrant proliferative signals and exposure to
chemotherapeutic drugs. However, increased p53 protein levels
are not sufficient for its activation. Rather, the modulation of
p53 activity occurs via phosphorylation, acetylation, glycosyla-
tion, ribosylation, ubiquitination or sumoylation, of p53,
thereby altering its DNA-binding ability or affinity for negative
regulators [13]. Post-translational modifications that increase
the ability of p53 to bind specific gene sequences and activate
gene transcription, ultimately lead to either cell cycle arrest or
apoptosis [13,14]. Numerous studies have demonstrated that
p53 directly activates the transcription of a number of genes
including p21WAF1/CIP1 [15], the major mediator of p53 cell-
cycle inhibitory capacity, and the apoptotic genes BAX [16],
PUMA [17], NOXA [18], p53AIP [19] and FAS/APO1 [20]. It
has also been shown to transcriptionally repress BCL-2 [21]. It
is not entirely clear how p53 modulates apoptosis and the role of
transcriptional activation and repression [22]. In fact, p53 has
been shown to translocate to the mitochondria where it is
directly apoptogenic, forming complexes with anti-apoptotic
Bcl-2 family proteins. This allows the release of sequestered
pro-apoptotic proteins and subsequent permeabilization of the
outer mitochondrial membrane [23,24].
p53 is the most commonly mutated tumor suppressor gene
in human cancers. However, the relationship between p53
status and sensitivity to chemotherapeutic drugs, including 5-
FU, is still controversial. 5-FU- and cisplatin-induced
apoptosis was significantly increased after wild-type p53
transfection in otherwise resistant cell lines [25]. In addition,
p53 disruption rendered colon cancer cells resistant to 5-FU,
both in vitro and in vivo [8]. However, both pre-clinical and
clinical studies have failed to associate p53 status with survival
after 5-FU adjuvant chemotherapy [26], or surgery+5-FU-
based chemotherapy [27]. Thus, p53 mutational status and/or
increased p53 immunostaining does not appear to be an
independent predictor of poor prognosis in colon cancer [28].
In contrast, other studies have shown an association of normal
p53 with improved colon cancer prognosis. In a well-defined
population of 391 patients with stage III colon cancer treated
with 5-FU adjuvant chemotherapy, mutant p53 was associated
with shorter disease-free survival, both in univariate and
multivariate analysis [29]. Another study using tumor tissue
from phase III surgical adjuvant trials also showed that normal
p53 and 5-FU-based treatment were significantly associated
with improved overall survival and also disease-free survival
[30].
Despite the controversy, the majority of human tumor
mutations decrease the sequence-specific DNA binding affinityand the transcriptional activity of p53 protein [31]. This may
account for acquired chemoresistance to anticancer drugs due to
failure of cells to undergo apoptosis [13,32]. In contrast to the
mitochondrial pathway, inactivation of the death receptor
apoptotic pathway is not frequent nor a prerequisite for tumor
development. In fact, tumor cells frequently present intact death
receptor signaling pathways [33]. Several chemotherapeutic
agents have been shown to up-regulate Fas death receptor
expression in cancer cell lines of different origin, including
colorectal cancer [34,35]. Loss of p53 function has also been
reported to affect the ability of cancer cells to up-regulate the
Fas receptor in response to chemotherapy [5,6].
In this study, we further investigated the apoptotic pathways
activated by 5-FU in a particular HCT116 cancer cell line. Our
results confirm that Fas is up-regulated by 5-FU in a p53-
dependent manner. Silencing Fas expression abrogated the
sensitivity to 5-FU-induced apoptosis. Further, 5-FU increased
p53 and Bax mitochondrial translocation, thus amplifying
apoptosis via the mitochondrial pathway.
2. Materials and methods
2.1. Cell culture and induction of apoptosis
HCT116 cells were grown in DMEM culture medium (Invitrogen Corp.,
Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Invitrogen
Corp.), 1% L-glutamine 200 mM (Merck and Co. Inc., NJ, USA) and 1%
antibiotic/antimycotic solution (Sigma Chemical Co., St. Louis, MO, USA), and
maintained at 37 °C in a humidified atmosphere of 5% CO2. Cells were plated at
either 1×105 cells/cm2 for morphological assessment of apoptosis and viability
assays, or 2×105 cells/cm2 for protein extraction and transfection assays. Cells
were then incubated in culture medium containing 1, 4 or 8 μM 5-FU (Sigma
Chemical Co.) in dimethyl sulfoxide (final concentration<0.1%), or no addition
(control) for 8, 24 or 48 h. Cells were fixed for microscopic assessment of
apoptosis or processed for cell viability assays. In addition, total and cytosolic
proteins were extracted for immunoblotting and caspase activity.
2.2. Evaluation of cell death and apoptosis
Cell death was measured by trypan blue dye exclusion. Hoechst labeling of
cells was used to detect apoptotic nuclei. Briefly, the medium was gently
removed at the indicated times to prevent detachment of cells. Attached cells
were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS), pH
7.4, for 10 min at room temperature, incubated with Hoechst dye 33258 (Sigma
Chemical Co.) at 5 μg/ml in PBS for 3 min, washed with PBS and mounted
using PBS:glycerol (3:1, v/v). Fluorescent nuclei were scored blindly by
laboratory personnel and categorized according to the condensation and staining
characteristics of chromatin. Normal nuclei showed non-condensed chromatin
dispersed over the entire nucleus. Apoptotic nuclei were identified by condensed
chromatin, contiguous to the nuclear membrane, as well as nuclear fragmenta-
tion of condensed chromatin. Three random microscopic fields per sample of
∼100 nuclei were counted and mean values expressed as the percentage of
apoptotic nuclei.
2.3. Caspase activation
Caspase activity was determined in cytosolic protein extracts after
harvesting and homogenization of cells in isolation buffer, containing 10 mM
Tris–HCl buffer, pH 7.6, 5 mM MgCl2, 1.5 mM potassium acetate, 2 mM
dithiothreitol, and protease inhibitor mixture tablets (Complete; Roche Applied
Science, Mannheim, Germany). General caspase-3, -8 and -9-like activities were
determined by enzymatic cleavage of chromophore p-nitroanilide (pNA) from
the substrate N-acetyl-Asp-Glu-Val-Asp-pNA (DEVD-pNA), N-acetyl-Ile-Glu-
Fig. 1. 5-FU-induced cytotoxicity in the HCT116 colon cancer cell line. Cells
were harvested for general cell death evaluation by trypan blue dye exclusion.
Percentage of cell death after incubation with 8 μM 5-FU, or no addition
(0 μM; control) for 48 h (left). Percentage of cell death after incubation with
8 μM 5-FU, or no addition (control) for 8, 24 and 48 h (right). The total
number of HCT116 cells before and after 8 μM 5-FU for 48 h was 1×105 and
0.58×105/cm2, respectively. Results are expressed as mean±SD of at least
three independent experiments. *p<0.001 and †p<0.01 from controls.
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pNA) (Sigma Chemical Co.), respectively. The proteolytic reaction was
carried out in isolation buffer containing 50 μg cytosolic protein and 50 μM
of specific caspase substrate. The reaction mixtures were incubated at 37 °C
for 1 h, and the formation of pNA was measured at 405 nm using a 96-well
plate reader.
2.4. Short interference RNA and transfections
To evaluate the role of Fas membrane receptor in 5-FU-induced cell
death, we performed Fas gene silencing assays. Briefly, we used a 25-
nucleotide duplex short interference RNA (siRNA) sequence targeting human
Fas mRNA, designed to knock down human Fas gene expression (Santa Cruz
Biotechnology, Santa Cruz, CA). At 24 h after plating, cells at ∼70%
confluence were transfected with Fas siRNA using JetSI Transfection Reagent
for siRNA (Polyplus-Transfection, Illkirch, France), at 50 nM, according to
the manufacturer's instructions. Twenty four hours after transfection, cells
were incubated with 8 μM 5-FU or no addition for 24 h, after which all
floating and attached cells were harvested for cytosolic and total protein
extraction. Hoechst labeling of cells was used to detect apoptotic nuclei as
described above. To assess gene silencing, Fas protein levels were evaluated
by immunoblotting.
2.5. Mitochondrial fractionation
Mitochondrial levels of cytochrome c, p53 and Bax were determined using
mitochondrial protein extracts from cells treated with 8 μM 5-FU for 24 h, or no
addition. Cells were harvested and centrifuged at 600×g for 5 min at 4 °C. The
pellets were washed once in ice-cold PBS and resuspended with 3 volumes of
isolation buffer containing 20 mM HEPES/KOH, pH 7.5, 10 mM KCl, 1.5 mM
MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and supplemented
with protease inhibitor cocktail tablets (Roche Applied Science), in 250 mM
sucrose. After chilling on ice for 15 min, cells were disrupted by 40 strokes on a
glass homogenizer, and homogenates centrifuged twice at 2500×g for 10 min at
4 °C to remove unbroken cells and nuclei. The mitochondrial fraction was then
centrifuged at 12,000×g for 30 min at 4 °C, and the pellet was resuspended in
isolation buffer.
2.6. Immunoblotting
Steady-state levels of p53, Bcl-2, Bax, poly (ADP-ribose) polymerase
(PARP), Fas, and caspase-3 proteins were determined by immunoblot analysis.
Briefly, 150 μg of total, 40 μg of cytosolic or 150 μg of mitochondrial protein
extracts were separated on 8, 12 or 14% SDS-polyacrylamide electrophoresis
gels. Following electrophoretic transfer onto nitrocellulose membranes,
immunoblots were incubated with 15% H2O2 for 15 min at room temperature.
After blocking with 5%milk solution, the blots were incubated overnight at 4 °C
with primary mouse monoclonal antibodies reactive to p53, Bax, Bcl-2, Fas
(Santa Cruz Biotechnology), cytochrome c (BD Biosciences PharMingen, San
Diego, CA) and cytochrome c oxidase subunit II (Molecular Probes, Eugene,
OR), or primary rabbit polyclonal antibodies for PARP and caspase-3 (Santa
Cruz Biotechnology). Finally, membranes were incubated with secondary
antibodies conjugated with horseradish peroxidase (Bio-Rad Laboratories,
Hercules, CA, USA) for 3°h at room temperature. The membranes were
processed for protein detection using Super Signal™ substrate (Pierce,
Rockford, IL, USA). β-actin was used as a loading control. Protein
concentrations were determined using the Bio-Rad protein assay kit according
to the manufacturer's specifications.
2.7. Densitometry and statistical analysis
The relative intensities of protein bands were analyzed using the
ImageMaster 1D Elite v4.00 densitometric analysis program (Amersham
Biosciences, Piscataway, NJ, USA). All data were expressed as mean±SEM
from at least three separate experiments. Statistical analysis was performed using
GraphPad InStat v3.00 (GraphPad Software, San Diego, CA) for the Student's t-
test. Values of p<0.05 were considered significant.3. Results
3.1. Sensitivity of colon cancer cells to 5-FU
We initially evaluated 5-FU cytotoxicity in wild-type p53
HCT116 cells. Our results showed that general cell death, as
measured by trypan blue dye exclusion, increased up to 2-fold
after supplementation with 5-FU for 48 h (p<0.001). This effect
was dose-dependent, with a maximum response with 8 μM 5-
FU (Fig. 1, left panel). Similarly, a time-response assay showed
that 8 μM 5-FU induced significant cell death in HCT116 cells
at 24 h (p<0.01), and this continued to increase at least up to
48 h (p<0.001) (Fig. 1, right panel). Exposure to 0.1% dimethyl
sulfoxide solvent alone did not significantly alter cell death
(data not shown).
3.2. Induction of apoptosis by 5-FU
It is well established that tumor cells exposed to anticancer
agents die from apoptosis; and those resistant to apoptosis are
able to survive anticancer treatment [1]. Coincubation experi-
ments with the pan-caspase inhibitor z-VAD.fmk strongly
prevented HCT116 cell death, suggesting that induction of
apoptosis plays an important role in 5-FU-injury to HCT116
cells (data not shown). In fact, high levels of apoptosis were
observed in HCT116 cells after 48 h incubation with 8 μM5-FU
as evaluated by Hoechst staining. The number of apoptotic cells
increased by >2-fold as compared with control cells (p<0.001)
(Fig. 2A).
3.3. 5-FU induces caspase-dependent apoptosis
Drug-induced apoptosis generally occurs through caspase-
dependent pathways [3,36]. We therefore evaluated caspase
activation after 5-FU treatment in HCT116 cells, using specific
colorimetric caspase substrates. Caspase-2 and -6 were not
significantly activated (data not shown). Caspase-8 activity was
almost 3-fold increased and caspase-3 and -9 activities were∼2-
Fig. 3. 5-FU increases p53 and Fas expression in p53-proficient cells. HCT116
cells were exposed to 8 μM 5-FU or no addition (control) for 48 h. Total proteins
were extracted for immunoblot analysis. Representative immunoblots of p53
and Fas expression and corresponding protein levels. Representative immuno-
blots of Bcl-2 and Bax are also shown. The results are expressed as mean±SEM
arbitrary units of at least five independent experiments. §p<0.05 from controls.
β-actin was used as a loading control.
Fig. 2. 5-FU induces apoptosis in HCT116 cells. Cells were fixed and stained for
morphological evaluation of apoptosis. Cytosolic and total proteins were
extracted for caspase activity assays and immunoblot analysis, respectively. (A)
Percentage of apoptosis in cells exposed to 8 μM 5-FU, or no addition (control)
for 48 h. (B) Caspase-8 and -9 activities in cytosolic protein extracts after
incubation with 8 μM 5-FU, or no addition (control) for 24 h. (C) Caspase-3
activity (left) and PARP cleavage (right) in protein extracts after incubation with
8 μM 5-FU, or no addition (control) for 24 h and 48 h, respectively. The results
are expressed as mean±SEM percentage or arbitrary units of at least three
independent experiments. *p<0.001 from controls. β-actin was used as a
loading control.
Fig. 4. Fas silencing reduces 5-FU-induced apoptosis in HCT116 cells. Cells were
transfected with Fas siRNAormock transfected at 24 h after platting. Twenty-four
hours after transfection, 8 μM 5-FU or no addition (control) were included for
additional 24 h. Total proteins were extracted for immunoblot analysis. In addi-
tion, cells were fixed and stained for morphological evaluation of apoptosis. (A)
Representative immunoblot of total Fas expression. (B) Percentage of apoptosis.
The results are expressed as mean±SEM percentage of at least three independent
experiments. *p<0.001 from control. β-actin was used as a loading control.
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(p<0.001) (Fig. 2B andC). In addition, the endogenous substrate
of active caspase-3, PARP, was cleaved in HCT116 cells. These
results demonstrate that 5-FU induces caspase-dependent
apoptosis through multiple classical apoptotic pathways.
3.4. 5-FU-induced apoptosis is associated with changes in p53
expression
Anticancer drugs including 5-FU promote DNA damage
[3,14]. The tumor suppressor p53 protein is normally up-
regulated in response to DNA insults, inducing cell-cycle arrest
and apoptosis via multiple different pathways [37]. We next
evaluated the effect of 5-FU on steady-state p53 levels in
HCT116 cells. Our results show that p53 expression was ∼25-
fold increased in cells treated with 8 μM 5-FU for 48 h
compared with untreated cells (p<0.05) (Fig. 3).
To further ascertain the mechanism by which 5-FU induces
apoptosis, we evaluated the steady-state levels of known
transcriptional targets of p53 involved in apoptosis, including
the Fas death receptor, pro-apoptotic Bax and anti-apoptotic
Bcl-2 (Fig. 3). Fas expression was >4-fold elevated in 5-FU-
treated HCT116 cells compared with untreated cells (p<0.05).
Bax and Bcl-2 protein levels did not change after 5-FU
incubation of HCT116 cells. This is not in itself sufficient to rule
out the involvement of the mitochondrial pathway in 5-FU-induced apoptosis. In fact, caspase-9 activity was increased by
5-FU in HCT116 cells.
3.5. Fas is required in 5-FU-induced apoptosis
To evaluate the functional role of the Fas death receptor in 5-
FU apoptotic signaling, we performed Fas siRNA-mediated
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with human Fas siRNA duplex or with a nonspecific control for
24 h, after which cells were incubated with 8 μM 5-FU or no
addition for another 24 h. Transfection with the nonsilencing
duplex did not significantly affect Fas protein levels relative to
untransfected controls (data not shown). Steady-state levels of
Fas protein expression were determined by western blot
analysis of total protein extracts. Fas gene silencing resulted
in a reduction of Fas protein expression by at least 70% in 5-FU-
treated HCT116 cells (Fig. 4A).
Having confirmed the effectiveness of Fas gene silencing,
we next evaluated nuclear fragmentation after Fas siRNA
transfection. Fas siRNA had negligible inherent cytotoxicity
(Fig. 4B). Importantly, Fas siRNA transfection prevented 5-FU-
induced nuclear fragmentation by 85% in HCT116 cells. To
determine the impact of Fas silencing in downstream molecular
effectors of apoptosis, caspase activities were also evaluated.
Transfection with Fas siRNA significantly prevented caspase-8
and -9 activities after 5-FU incubation by ∼80 and 40%,
respectively (Fig. 5A). The increase in caspase-3 activity
induced by 5-FU was also prevented in 65% by Fas siRNA (Fig.Fig. 5. Fas silencing reduces 5-FU-induced caspase activation in HCT116 cells.
Cells were transfected with Fas siRNA or mock transfected at 24 h after plating.
Twenty-four hours after transfection, 8 μM 5-FU or no addition (control) were
included for additional 24 h. Cytosolic proteins were extracted for caspase
activity and processing assays. (A) Caspase-8 and -9 activities. (B) Caspase-3
activity (left) and representative immunoblot of active caspase-3 (right). (C)
Representative immunoblot of total p53 expression. The results are expressed
as mean±SEM arbitrary units of at least three independent experiments.
*p<0.001 and §p<0.05 from controls. β-actin was used to control for lane
loading.
Fig. 6. 5-FU induces cytochrome c release and translocation of p53 and Bax to
the mitochondria in HCT116 cells. Cells were exposed to 8 μM 5-FU or no
addition (control) for 24 h. Mitochondrial proteins were extracted for
immunoblot analysis. Representative immunoblots of p53, Bax and cytochrome
c (Cyt c) and corresponding protein levels. The results are expressed as mean±
SEM arbitrary units of at least three independent experiments. *p<0.001 and
§p<0.05 from controls.5B). Thus, the Fas death receptor is essential for the onset of 5-
FU-induced apoptosis in p53-proficient cells. Finally, depletion
of Fas by siRNA partially inhibited induction of p53 after 5-FU
exposure in HCT116 cells (Fig. 5C).
3.6. 5-FU induces cytochrome c release and translocation of
p53 and Bax to the mitochondria
Drug-induced apoptosis has been reported to be dependent
on activation of the mitochondrial pathway [32]. Further, p53
may have a direct non-transcriptional effect in activating this
pathway [23,24,38]. To determine the role of the mitochondrial
pathway in 5-FU-induced apoptosis, we evaluated cytochrome
c in mitochondrial protein extracts from HCT116 cells
incubated with 8 μM 5-FU for 24 h. Our results showed that
5-FU reduced mitochondrial cytochrome c content by 3-fold
(Fig. 6) (p<0.001). Moreover, cytochrome c oxidase II was not
significantly changed in mitochondrial protein extracts and,
therefore, remained undetectable in the cytosolic fraction,
consistent with the absence of mitochondrial disruption (data
not shown).
It is thought that a portion of wild-type p53 lacking
transactivation activity, localizes to the mitochondria, where it
is capable of forming complexes with Bcl-2 and Bcl-XL,
thereby releasing sequestered pro-apoptotic members of the
Bcl-2 family, such as Bid and Bax. This is achieved through
direct physical interaction of p53 protein with anti-apoptotic
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incubation, mitochondrial p53 levels were increased in HCT116
cells (p<0.05). Further, consistent with cytochrome c release,
Bax mitochondrial levels were >6-fold increased (p<0.001).
These results show that 5-FU is capable of activating the
mitochondrial pathway of apoptosis. p53 may play a crucial
transcription-independent pro-apoptotic role in this cellular
context, probably interacting with anti-apoptotic mitochondria
localized proteins and allowing Bax to translocate to the
mitochondria, where it exerts its pro-apoptotic function.
4. Discussion
5-FU has been the most widely used drug for colorectal
cancer adjuvant chemotherapy for more than 4 decades.
However, chemoresistance remains a significant drawback to
its clinical success. Here, we provide further insight into the
molecular pathways activated by 5-FU in a HCT116 colon
cancer cell line. In these cells, most of the apoptotic activity is
mediated via Fas signaling in association with wild-type p53 as
evidenced by the use of siRNA Fas molecules. Moreover, p53
and Bax pro-apoptotic function at the organelle level may also
account for activation of the mitochondrial pathway of
apoptosis.
5-FU is a pro-apoptotic agent which can interfere with both
RNA and DNA metabolism. Further, its cytotoxicity has been
correlated with the presence of wild-type p53 protein [5,7,8].
However, some controversy exists regarding the predictive
value of p53 status on 5-FU-sensitivity as well as patient
survival. In the present study, we used HCT116 cells,
expressing both wild type p53 and Bax [39]. 5-FU resulted in
significant nuclear fragmentation of wild-type p53 HCT116
cells. Further, 5-FU increased caspase-8, -9 and -3 activities,
while markedly up-regulating p53 in HCT116 cells. These
results confirm that 5-FU-induced apoptosis is caspase-
dependent and associates with functional expression of wild-
type p53; however, they do not exclude that there might be non-
p53 dependent apoptosis in mutant p53 cells.
p53 plays a pivotal role in the cellular environment due to its
ability to “sense” cellular stresses and activate several molecular
signaling pathways. p53 can lead to cellular repair of the
sustained damage by induction of cell cycle arrest, or ultimately
to apoptotic cell death. Indeed, p53 is known to transactivate
several genes involved in apoptosis [16–20]. The results
presented here show that Fas was up-regulated after 5-FU
exposure in HCT116 cells. In contrast, Bax and Bcl-2 proteins
were not modulated. This indicates that 5-FU exerts its
cytotoxicity mainly through activation of the death receptor
pathway of apoptosis. However, increased caspase-9 activity by
5-FU suggests that some apoptotic signaling is proceeding
through a mitochondrial pathway. A known cross-talk between
the extrinsic and intrinsic pathways of apoptosis depends on
proteolytic activation of pro-apoptotic Bid protein by caspase-8
[40,41].
Fas is a well-known p53 transcriptional target. Further, it has
been suggested that 5-FU up-regulates Fas expression in p53-
proficient cells [5], but not in cells with mutant p53. However, ithas not been shown that Fas up-regulation by 5-FU is essential
for 5-FU-induced apoptosis in colon cancer cell lines. To
evaluate the role of Fas in 5-FU-induced apoptosis, we silenced
Fas gene expression at the post-transcriptional level using
siRNA technology, and exposed cells to 5-FU. Our results
showed that Fas gene silencing resulted in an almost complete
abrogation of apoptosis in HCT116 cells. Caspase-8 and -3, and
to a lesser extent caspase-9, activities were also largely
prevented. This indicates that Fas signaling is responsible for
most of 5-FU apoptotic signaling in p53-proficient colon cancer
cells. However, the results do not entirely exclude involvement
of the mitochondrial pathway in mediating 5-FU apoptotic
signaling; and, in fact, suggest an alteration in cross-talk
between the pathways.
It has recently been shown that p53 is able to translocate to
mitochondria both in vitro [23] and in vivo [38,42]. Thus, p53
appears to play a direct pro-apoptotic role associated with
permeabilization of the mitochondria and release of apopto-
genic factors, such as cytochrome c [38,43]. In this study, 5-FU
increased the fraction of mitochondrial p53 and induced
cytochrome c release in HCT116 cells, indicating activation
of the mitochondrial pathway. Interestingly, 5-FU was also able
to increase the translocation of pro-apoptotic protein Bax to the
mitochondria. These results suggest that p53 might also play a
transcription-independent function in HCT116 cells exposed to
5-FU, probably by interacting with anti-apoptotic members of
the Bcl-2 family. Released Bax then permeabilizes the outer
mitochondrial membrane. Thus, the activation of the mitochon-
drial pathway of apoptosis is dependent on p53- and Bax-
proficiency. This supports previous reports showing that
disruption of both TP53 or Bax alleles in a colon cancer cell
line resulted in resistance to 5-FU-induced apoptosis [8,44].
However, it has also been demonstrated that 5-FU only partially
depends on Bax for induction of apoptosis via mitochondrial
membrane perturbation. Further, a significant amount of
apoptosis was observed in Bax-negative DU145 human prostate
carcinoma cells, following exposure to 5-FU [33].
Taken together, our results indicate that 5-FU-induced cell
death proceeds via activation of extrinsic and intrinsic pathways
of apoptosis in HCT116 cells. Further, the death receptor Fas is
pivotal in 5-FU-induced, wild-type p53-dependent apoptosis.
Silencing Fas significantly reduces tumor cell sensitivity to 5-
FU in the presence of wild-type p53 competence. Activation of
the mitochondrial pathway by 5-FU depends on p53 and Bax
and appears to have a lesser contribution to the overall cell death
rate. Finally, approaches that are directed at increasing 5-FU
activation of the intrinsic pathway of apoptosis might improve
the response to this colorectal cancer chemotherapy.
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